HLB Pharmaceutical Co., Ltd.'s (KOSDAQ:047920) lackluster earnings announcement last week disappointed investors. We looked deeper and believe that there is even more to be worried about, beyond the soft profit numbers.
In order to understand the potential for per share returns, it is essential to consider how much a company is diluting shareholders. HLB Pharmaceutical expanded the number of shares on issue by 134% over the last year. That means its earnings are split among a greater number of shares. Per share metrics like EPS help us understand how much actual shareholders are benefitting from the company's profits, while the net income level gives us a better view of the company's absolute size. Check out HLB Pharmaceutical's historical EPS growth by clicking on this link.
HLB Pharmaceutical has improved its profit over the last three years, with an annualized gain of 107% in that time. But EPS was only up 81% per year, in the exact same period. Net income was down 25% over the last twelve months. But the EPS result was even worse, with the company recording a decline of 29%. So you can see that the dilution has had a fairly significant impact on shareholders.
In the long term, if HLB Pharmaceutical's earnings per share can increase, then the share price should too. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of HLB Pharmaceutical.
Alongside that dilution, it's also important to note that HLB Pharmaceutical's profit was boosted by unusual items worth ₩212m in the last twelve months. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).
In its last report HLB Pharmaceutical benefitted from unusual items which boosted its profit, which could make the profit seem better than it really is on a sustainable basis. On top of that, the dilution means that its earnings per share performance is worse than its profit performance. Considering all this we'd argue HLB Pharmaceutical's profits probably give an overly generous impression of its sustainable level of profitability. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. For example, HLB Pharmaceutical has 3 warning signs (and 2 which are concerning) we think you should know about.
In this article we've looked at a number of factors that can impair the utility of profit numbers, and we've come away cautious. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.